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(http://creativecommois a risk factor for Alzheimer’s disease (AD) and dementia. Genetic variation in the cholesteryl ester
transfer protein (CETP) locus is associated with altered HDL-C. We aimed to assess AD risk by
genetically predicted HDL-C.
Methods: Ten single nucleotide polymorphisms within the CETP locus predicting HDL-C were
applied to the International Genomics of Alzheimer’s Project (IGAP) exome chip stage 1 results
in up 16,097 late onset AD cases and 18,077 cognitively normal elderly controls. We performed
instrumental variables analysis using inverse variance weighting, weighted median, and MR-Egger.
Results: Based on 10 single nucleotide polymorphisms distinctly predicting HDL-C in the CETP lo-
cus, we found that HDL-C was not associated with risk of AD (P . .7).
Discussion: Our study does not support the role of HDL-C on risk of AD through HDL-C altered by
CETP. This study does not rule out other mechanisms by which HDL-C affects risk of AD.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Genetics; HDL-C; Single nucleotide polymorphisms; Instrumental variables; Cholesteryl ester transfer protein1. Introduction
Alzheimer’s disease (AD) is an incurable neurological
disease affecting more than 5 million individuals living in
the United States [1]. A potential connection between
cholesterol levels and risk of AD and dementia has been sug-
gested [2]. This is important as cholesterol levels in blood
can be modified. However, there is conflicting epidemiolog-
ical evidence whether high-density lipoprotein cholesterol
(HDL-C) levels, which is considered the beneficial choles-
terol, is a risk factor for AD and dementia. In a prospective
study of approximately 7000 French individuals, there was
no association of HDL-C with incident all-cause dementiadeclared that no conflict of interest exists.
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ns.org/licenses/by/4.0/).or AD [3]. On the other hand, in the same French cohort,
an association was observed in men between incident all-
cause dementia, but not AD [4], and in a study of 75,000
individuals in Denmark, HDL-C was associated with both
all-cause dementia and AD [5]. When evidence was com-
bined from multiple published studies, late-life HDL-C
was not associated with all-cause dementia or AD [6].
Cholesteryl ester transfer protein (CETP) is involved in
the exchange of cholesteryl esters and phospholipids be-
tween HDLs and other lipoproteins. Increased plasma
HDL-C and plasma CETP is linked to a reduced risk of car-
diovascular disease [7,8]. Common single nucleotide
polymorphisms (SNPs) in the CETP locus have been
strongly linked to altered plasma lipid levels [9]. Further-
more, protein-truncating variants (i.e., nonsense, frameshift,
and splice site variants) in CETP are associated with highereimer’s Association. This is an open access article under the CC BY license
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glycerides, and lower risk of coronary heart disease [10].
The Global Lipids Genetic Consortium has reported 10 var-
iants on the exome array that are significantly and distinctly
associated with HDL-C [11]. These SNPs in CETP with
large effects on HDL-C can be used as tools to elucidate
whether there is a causal role of HDL-C on AD. In this study,
we use instrumental variable analysis with genetic instru-
ments (i.e., Mendelian Randomization) to predict whether
high HDL-C through CETP is associated with AD by
answering the questions: (1) Do CETP SNPs associate
with AD risk?; and (2) Does genetically predicted high
HDL-C through CETP associate with risk of AD?
2. Methods
2.1. Association statistics
We obtained results for 10 SNPs previously shown to be
strongly and distinctly associated with HDL-C in the CETP
region (Table 1) from the Global Lipids Genetic Consortium
exome chip results in up to 316,391 individuals, mostly of
European origin [10,11]. HDL-C was measured by standard
protocols, and the majority of individuals were fasting [11].
The analysis of HDL-C was adjusted for age, sex, population
stratification, and relatedness, where appropriate, and in-
verse normalized residuals were used as outcomes. Results
were meta-analyzed across cohorts using an additive model.
The CETP region was defined as being within 1 MB of an
indexed CETP SNP (rs3764261).
We obtained results for the 10 identified CETP SNPs with
ADwithin the IGAPexome chip results in up to 34,174 individ-
uals from the stage 1 results (up to 16,097 late onset AD cases
and 18,077 cognitively normal elderly controls) [12]. Results
from multiple consortia were meta-analyzed using an additive
model. Two sets of covariates were used in the model of asso-
ciation: principal components (PCs) of ancestry only adjust-
ment (model 1) and PCs, age and sex adjustment (model 2).
Both sets of results were based on exome chip genotypes
and aligned to the forward strand.Table 1
GLGC and IGAP exome chip results for 10 SNPs in the CETP region distinctly a
SNP Protein Effect allele Frequency
HDL-C
b SE P
rs2303790 ASP459GLY G 0.08% 0.366 0.047 5
rs34065661 ALA15GLY G 0.48% 0.435 0.020 6
rs247616 Intergenic T 30.83% 0.242 0.003 ,
rs3764261 Intergenic A 31.27% 0.239 0.003 ,
rs173539 Intergenic T 32.26% 0.230 0.003 ,
rs5882 VAL422ILE G 35.04% 0.092 0.003 6
rs9989419 Intergenic G 60.09% 0.131 0.003 ,
rs9939224 Intronic G 78.73% 0.205 0.003 ,
rs7499892 Intronic C 80.83% 0.230 0.003 ,
rs5880 ALA390PRO G 95.19% 0.258 0.007 4
Abbreviations: AD, Alzheimer’s deisease; GLGC, Global Lipids Genetic Conso
components; SNPs, single nucleotide polymorphisms; CETP, cholesteryl ester tra
NOTE. AD model 1 adjusts for PCs of ancestry only.
NOTE. AD model 2 adjusts for PCs of ancestry, age, and sex.2.2. Statistical analyses
We obtained CETP-predicted estimates of the effect of
HDL-C on risk of AD from summary statistics using fixed
effects inverse variance weighted meta-analysis [13],
weighted median method [14], and MR-Egger [15]. A
non-zero MR-Egger intercept indicates that the inverse vari-
ance weighted estimate may be invalid. We report the odds
ratio and 95% confidence intervals per standard deviation
of HDL-C.
Our primary analysis is based on the 10 previously re-
ported HDL-C SNPs in the CETP locus with the model 1
adjusted AD results. We perform sensitivity analyses on
the following sets of SNPs to determine whether the set
of SNPs or AD model adjustment influenced the results:
(1). 10 HDL-C SNPs with model 2 AD results, (2). 9
HDL-C SNPs with consistent AD effects using model 2
AD results, (3). 7 common HDL-C SNPs with model
2 AD results, (4). 4 nonsynonymous SNPs with model 1
AD results, and (5). 4 nonsynonymous SNPs with model
2 AD results.
All statistical analyses were conducted using the R pack-
age Mendelian Randomization in R, version 3.3.1 (R Foun-
dation for Statistical Computing, Vienna, Austria). Only
summary statistics were used in this study.
2.3. Power calculation
The 10 CETP SNPs explainw3.5% of variance of HDL-C
[11]. We calculated the power to detect an effect of HDL-C
through CETP on AD through Mendelian randomization [16]
given our sample (34,174 individuals, 47% cases) assuming
the SNPs explain 3.5% of the variance in HDL-C at an alpha
of 0.05 using http://cnsgenomics.com/shiny/mRnd/.3. Results
Ten SNPs in CETP region were shown to distinctly and
significantly associate with HDL in the Global Lipids Ge-
netic Consortium exome chip analyses (Table 1). Eight ofssociated with plasma HDL-C levels
AD model 1 AD model 2
value b SE P value b SE P value
! 10215 0.280 1.419 0.844 20.801 1.703 0.638
! 102103 0.034 0.307 0.912 0.142 0.334 0.670
1! 102323 20.004 0.018 0.812 0.003 0.020 0.879
1! 102323 0.004 0.018 0.832 20.003 0.020 0.880
1! 102323 20.008 0.018 0.679 20.001 0.020 0.959
! 102241 0.002 0.018 0.908 20.009 0.020 0.640
1! 102323 20.002 0.018 0.892 0.002 0.020 0.906
1! 102323 0.026 0.021 0.220 0.029 0.023 0.201
1! 102323 20.030 0.022 0.187 20.035 0.024 0.151
! 102321 20.017 0.045 0.705 0.002 0.050 0.970
rtium; IGAP, International Genomics of Alzheimer’s Project; PC, principal
nsfer protein; HDL-C, high-density lipoprotein cholesterol.
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tion effect on HDL-C. We associated these 10 SNPs with
AD in the IGAP exome chip results. None of the ten
CETP SNPs were nominally associated with
AD (P . .05). All the AD results had heterogeneity
P value . 0.1.
We compared the AD effect estimates between the PC
only adjusted model (model 1) and the PC plus age
and sex adjusted model (model 2) for the 10 CETP region
SNPs. We found that one SNP (rs2303790)
with discordant effect size between the two AD models
(Supplementary Fig. 1A). After removing rs2303790,
we found a 0.81 correlation between the effect estimates
from the two AD model adjustments (P 5 .0075)
(Supplementary Fig. 1B). In both adjustment
models, we found a positive trend between each SNPs ef-
fect on HDL with its corresponding effect on AD
(Supplementary Fig. 1C and D).
Across six sets of results and three statistical models, we
found no evidence that genetically increasing HDL-C
through CETP will lead to an increase in risk of AD
(Table 2). MR-Egger intercepts were not found to be
different from zero, suggesting that directional pleiotropy
was not apparent, and the I2 estimate was .99% in all ana-
lyses, indicating variability in effects.
Given our sample size (34,174 individuals, 47% cases)
and the proportion of variance explained in HDL by the
CETP SNPs (3.5%), we had .80% power to detect an
odds ratio . 1.18 or , 0.85 for genetically increased HDL
on risk of AD at an alpha of 0.05.Table 2
Estimates of the effect of genetically predicted HDL-C through CETP on AD
Model OR (95% CI) P va
10 HDL SNPs, model 1 AD results
Inverse variance weighted 0.988 (0.923, 1.059) 0.73
Weighted Median 0.982 (0.9, 1.07) 0.68
MR-Egger 0.956 (0.751, 1.217) 0.71
10 HDL SNPs, model 2 AD results
Inverse variance weighted 0.995 (0.924, 1.071) 0.89
Weighted Median 0.999 (0.908, 1.099) 0.98
MR-Egger 1.013 (0.78, 1.318) 0.92
9 HDL SNPs with consistent AD effects, model 2 AD results
Inverse variance weighted 0.995 (0.924, 1.073) 0.89
Weighted Median 0.999 (0.909, 1.097) 0.98
MR-Egger 1.014 (0.78, 1.318) 0.91
7 Common HDL SNPs, model 2 AD results
Inverse variance weighted 0.994 (0.921, 1.073) 0.87
Weighted Median 0.997 (0.906, 1.097) 0.94
MR-Egger 1.008 (0.771, 1.317) 0.95
4 nonsynonymous SNPs, model 1 AD results
Inverse variance weighted 0.977 (0.76, 1.257) 0.85
Weighted Median 0.976 (0.746, 1.276) 0.86
MR-Egger 0.91 (0.526, 1.576) 0.73
4 nonsynonymous SNPs, model 2 AD results
Inverse variance weighted 0.97 (0.736, 1.279) 0.82
Weighted Median 0.964 (0.72, 1.289) 0.80
MR-Egger 1.101 (0.602, 2.014) 0.75
Abbreviations: HDL-C, high-density lipoprotein cholesterol; CETP, cholestery
polymorphisms; CI, confidence interval.4. Discussion
Wefound that SNPs in theCETP locuswith a large effect on
HDL-C were not associated with risk of AD and that geneti-
cally predicted HDL-C, through polymorphisms in the
CETP locus, does not associate with risk of AD. Our study
lends evidence that life-long altered HDL-C through CETP
is not a causal predictor of risk of AD. Previously, Proitsi
et al. showed no association between a genetic risk score of
157 lipid SNPs weighted by their HDL-C effect and AD in
up to 10,578 individuals [17].While Proitsi et al. used a genetic
risk score of all genome-wide associated SNPs, we focused on
one mechanism of raising HDL-C, through the gene CETP.
The strengths of our study include the large sample sizes
that were used for the summary statistics allowing for precise
estimates of effect and themultiple statistical analysespointing
to the same conclusion. Despite the large samples andmultiple
methods, limitations of our study are as follows. First, we had
power to detect odds ratios .1.18 or ,0.85 for genetically
increased HDL-C on risk of AD. If there is a smaller effect
of HDL-C on AD, we may not have been able to detect it.
Another study showed that variation in CETP associated
with higher HDL-C is also associated with an increased risk
of intracerebral hemorrhage [18]. We used the same set of
SNPs. Second, CETP SNPs are also known to be associated
with other lipid levels and therefore the other lipid fractions
(i.e., lower low-density lipoprotein cholesterol or triglycer-
ides) may hide a true relationship between HDL-C and AD.
Third, our study focused on the effects of HDL-C in the popu-
lation, and we were not able to determine whether extreme
HDL-C levels through CETP have an association with AD.lue MR-Egger intercept (P value) I2 (P value)
8
2 0.007 (0.775) 100% (0.896)
5
4
20.004 (0.885) 100% (0.824)
8
4
5 20.004 (0.881) 99.9% (0.765)
3
6
6 20.003 (0.916) 99.9% (0.557)
8
8 0.010 (0.777) 99.9% (0.953)
9
3
6 20.019 (0.645) 99.9% (0.833)
l ester transfer protein; AD, Alzheimer’s deisease; SNPs, single nucleotide
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causal effect onAD, and these cannot be elucidated by the pre-
sent study. Fifth, the studies that contributed to the results were
predominately of European origin and therefore we cannot
generalize these results to other ancestries.
Despite the promise of high HDL-C providing protection
for AD, we do not find evidence that increasing HDL-C
through the CETP will result in lower risk for AD.Acknowledgments
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1. Systematic review: The connection between choles-
terol levels and risk of Alzheimer’s disease (AD)
and dementia has been suggested as a promising
avenue for risk prediction as well as risk reduction.
There is conflicting evidence whether high-density
lipoprotein cholesterol (HDL-C) levels are a risk
factor for AD and dementia.
2. Interpretation:Weperformeda studywith large sample
sizes to look at whether genetically predicted HDL-C
through cholesteryl ester transfer protein is associated
with risk of AD.We found that single nucleotide poly-
morphisms in the cholesteryl ester transfer protein lo-
cus with a large effect on HDL-C were not associated
with risk of AD, and that genetically predicted HDL-
C through cholesteryl ester transfer protein did not
associate with risk of AD, suggesting that high HDL-
C does not provide protection for AD.
3. Future directions: This study does not rule out other
mechanisms by which HDL-C affects risk of AD;
these should be explored.References
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